Galecto, Inc. (GLTO)
| Market Cap | 313.35M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -47.88M |
| Shares Out | 24.59M |
| EPS (ttm) | -1.95 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 25 |
| Last Price | $12.60 |
| Previous Close | $12.27 |
| Change ($) | 0.33 |
| Change (%) | 2.69% |
| Day's Open | 12.37 |
| Day's Range | 12.35 - 12.92 |
| Day's Volume | 9,393 |
| 52-Week Range | 12.20 - 16.84 |
BOSTON, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc., (NASDAQ: GLTO) a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today anno...
BOSTON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today anno...
Successfully completed listing on US Nasdaq and raised over $ 150 million during recent IPO and preceding crossover round
BOSTON and COPENHAGEN, Denmark, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Galecto, Inc., a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, a...
BOSTON and COPENHAGEN, Denmark, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibros...
The IPO market is taking a break during the shortened Thanksgiving week, with just one IPO and two SPACs scheduled to raise $900 million. Russian e-commerce company Ozon Holdings plans to rais...
Eleven IPOs and nine SPACs priced this past week, getting out ahead of the US election. Markets tumbled and volatility spiked, as several deals broke issue and three IPOs postponed.
BOSTON and COPENHAGEN, Denmark, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company developing therapeutics that are designed to target the b...
Galecto has filed proposed terms for an $85 million U.S. IPO. The firm is development treatments for various fibrosis diseases.
About GLTO
Galecto, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral galect... [Read more...]
| Industry Biotechnology | IPO Date Oct 29, 2020 |
| CEO Hans T. Schambye | Employees 23 |
| Stock Exchange NASDAQ | Ticker Symbol GLTO |
Analyst Forecasts
According to 3 analysts, the average rating for Galecto stock is "Strong Buy." The 12-month stock price forecast is 24.75, which is an increase of 96.43% from the latest price.